[go: up one dir, main page]

WO2011138265A3 - Indole and indazole derivatives as orexin receptor antagonists - Google Patents

Indole and indazole derivatives as orexin receptor antagonists Download PDF

Info

Publication number
WO2011138265A3
WO2011138265A3 PCT/EP2011/056938 EP2011056938W WO2011138265A3 WO 2011138265 A3 WO2011138265 A3 WO 2011138265A3 EP 2011056938 W EP2011056938 W EP 2011056938W WO 2011138265 A3 WO2011138265 A3 WO 2011138265A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
indole
orexin receptor
indazole derivatives
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/056938
Other languages
French (fr)
Other versions
WO2011138265A2 (en
Inventor
Jonathan Mark Bentley
Tara Davenport
Mark Slack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec OAI AG
Original Assignee
Evotec OAI AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec OAI AG filed Critical Evotec OAI AG
Publication of WO2011138265A2 publication Critical patent/WO2011138265A2/en
Anticipated expiration legal-status Critical
Publication of WO2011138265A3 publication Critical patent/WO2011138265A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The invention relates to compounds of formula (I) wherein A, R1 to R8 have the meaning as cited in the description and the claims. Said compounds are useful as Orexin Receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
PCT/EP2011/056938 2010-05-03 2011-05-02 Indole and indazole derivatives as orexin receptor antagonists Ceased WO2011138265A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10161735.5 2010-05-03
EP10161735 2010-05-03

Publications (2)

Publication Number Publication Date
WO2011138265A2 WO2011138265A2 (en) 2011-11-10
WO2011138265A3 true WO2011138265A3 (en) 2015-06-25

Family

ID=42732252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/056938 Ceased WO2011138265A2 (en) 2010-05-03 2011-05-02 Indole and indazole derivatives as orexin receptor antagonists

Country Status (1)

Country Link
WO (1) WO2011138265A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
SG11201404738QA (en) 2012-02-07 2014-10-30 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
ITMI20130830A1 (en) 2013-05-22 2014-11-23 Laboratorio Chimico Int Spa PROCEDURE FOR THE PREPARATION OF IVABRADINA
UY36272A (en) 2014-08-13 2016-02-29 Eolas Therapeutics Inc DIFLUOROPIRROLIDINS AS MODULATORS OF OREXIN RECEPTORS
JO3719B1 (en) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- Oxo-4,3-dihydro-3,2,1-benzotriazines as controls for GPR139
JP6883045B2 (en) 2016-02-12 2021-06-02 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Halo-substituted piperidine as an orexin receptor regulator
PH12022550597A1 (en) 2019-09-16 2024-03-04 Takeda Pharmaceuticals Co Azole-fused pyridazin-3(2h)-one derivatives
WO2022119864A1 (en) * 2020-12-01 2022-06-09 Purdue Research Foundation Compounds for the treatment of sars
AU2024249981A1 (en) 2023-04-06 2025-10-16 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046199A2 (en) * 1999-02-05 2000-08-10 Astrazeneca Ab Indole derivatives as anti-inflammation agents
WO2000047577A1 (en) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
WO2000047576A1 (en) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
WO2005040114A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds having crth2 antagonist activity
WO2009105722A1 (en) * 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001260113B2 (en) 2000-03-14 2006-04-06 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
DE60110066T2 (en) 2000-06-16 2006-02-02 Smithkline Beecham P.L.C., Brentford Piperidines for use as orexin receptor agonists
WO2002089800A2 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
PL373223A1 (en) 2002-07-09 2005-08-22 Actelion Pharmaceuticals Ltd. 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives
AU2007285371A1 (en) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd. Azetidine compounds as orexin receptor antagonists
EP2161266A1 (en) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Benzofuran derivatives as orexin receptor antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046199A2 (en) * 1999-02-05 2000-08-10 Astrazeneca Ab Indole derivatives as anti-inflammation agents
WO2000047577A1 (en) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
WO2000047576A1 (en) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
WO2005040114A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds having crth2 antagonist activity
WO2009105722A1 (en) * 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity

Also Published As

Publication number Publication date
WO2011138265A2 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
WO2011138265A3 (en) Indole and indazole derivatives as orexin receptor antagonists
IN2014CN04127A (en)
MX2010003001A (en) Quinoline derivatives as 5ht5a receptor antagonists.
MX2011011428A (en) Sulfamoyl benzoic acid derivatives as trpm8 antagonists.
WO2012088038A3 (en) Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
MY169986A (en) Benzimidazole-proline derivatives
WO2009016564A3 (en) 2-aza-bicyclo[3.3.0]octane derivatives
UA110310C2 (en) Compounds n-aryl triazole as antagonists receptors lisophosphatidic acid (lpar)
ATE493386T1 (en) TRANS-3-AZA-BICYCLO-Ä3.1.0Ü-HEXANE DERIVATIVES
ATE483707T1 (en) 2-CYCLOPROPYLTHIAZOLE DERIVATIVES
WO2009022311A3 (en) 1,2-diamido-ethylene derivatives as orexin antagonists
MX2010008993A (en) 2-aza-bicyclo[2.2.1]heptane derivatives.
WO2012088124A3 (en) Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
UA107334C2 (en) Alkaloid aminoester derivatives and their drug compositions
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
WO2010049449A3 (en) Novel salts of sunitinib
WO2013190508A3 (en) 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives
WO2011050054A3 (en) Coumarin compounds as receptor modulators with therapeutic utility
WO2010140139A3 (en) Crystalline forms of 6-(1h- imadazol- 1-yl) -2-phenylquinazoline
WO2010131192A3 (en) Novel oxazolidinone derivatives and their use as orexin receptor antagonists
HK1259248A1 (en) Novel 1,2-bis-sulfonamide derivatives as chemokine receptor modulators
WO2009034432A3 (en) Novel compounds active as muscarinic receptor antagonists
WO2011156045A3 (en) Tablet formulation of ezatiostat
WO2011125006A3 (en) Sultam compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11718036

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 04.02.2013

122 Ep: pct application non-entry in european phase

Ref document number: 11718036

Country of ref document: EP

Kind code of ref document: A2